Shares of NGM Biopharmaceuticals (NASDAQ:NGM) are tanking today after the topline results from its Phase 2 study of NGM621 for the treatment of geographic atrophy  (GA) secondary to age-related macular degeneration (AMD) showed that the drug failed to meet the primary endpoints. Further details and findings from this study are anticipated in November at the Retina Society annual meeting.
https://www.tipranks.com/news/ngm-bio-tanks-after-ngm621-fails-in-phase-2-study?utm_source=advfn.com&utm_medium=referral
NGM Biopharmaceuticals (NASDAQ:NGM)
Gráfico Histórico do Ativo
De Fev 2023 até Mar 2023 Click aqui para mais gráficos NGM Biopharmaceuticals.
NGM Biopharmaceuticals (NASDAQ:NGM)
Gráfico Histórico do Ativo
De Mar 2022 até Mar 2023 Click aqui para mais gráficos NGM Biopharmaceuticals.